Dogwood Therapeutics DWTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.46K— | —— | —— | —— | —— | ||
| $2.67M+14.2% | $2.34M-83.9% | $14.52M+465% | $2.57M+5.5% | $2.44M+5.2% | ||
| $2.41M+63.9% | $1.47M+14.0% | $1.29M-4.8% | $1.35M-32.1% | $1.99M-61.9% | ||
| $5.08M+33.4% | $3.81M-75.9% | $15.81M+303% | $3.92M-11.4% | $4.43M-41.3% | ||
| $5.08M+33.4% | $3.81M-75.9% | $15.81M+303% | $3.92M-11.4% | $4.43M-41.3% | ||
| -$5.08M-33.4% | -$3.81M+75.9% | -$15.81M-303% | -$3.92M+11.4% | -$4.43M+41.3% | ||
| $77.35K+48.6% | $52.07K-35.4% | $80.58K-27.7% | $111.38K+176% | -$147.09K+5.4% | ||
| $90.95K— | $0-100% | $63.07K-45.6% | $115.91K+102% | -$6.3M-3,285% | ||
| —— | —— | —— | —— | -$6.13M— | ||
| —— | -$682.750.0% | -$682.750.0% | -$682.750.0% | -$682.75— | ||
| -$4.99M-33.0% | -$3.75M+76.2% | -$15.75M-314% | -$3.81M+64.5% | -$10.73M-38.9% | ||
| -$4.99M-31.9% | -$3.78M+76.0% | -$15.74M-314% | -$3.81M+65.1% | -$10.92M-41.4% | ||
| -$0.15— | —— | -$8.20-312% | -$1.99+76.4% | -$8.45-11.6% | ||
| -$0.15— | —— | -$8.20-312% | -$1.99+76.4% | -$8.45-11.6% | ||
| 33.5M+574% | 5M+159% | 1.9M+0.4% | 1.9M+32.6% | 1.4M+40.3% | ||
| 33.5M+574% | 5M+159% | 1.9M+0.4% | 1.9M+32.6% | 1.4M+40.3% | ||
| $77.35K+48.6% | $52.07K-35.4% | $80.58K-27.7% | $111.38K+176% | -$147.09K+5.4% | ||
| -$6.12M-124% | -$2.73M+84.0% | -$17.11M-6,173% | -$272.81K+97.5% | -$10.86M+6.3% | ||
| $1.19K-96.3% | $31.84K+2,317% | -$1.44K-1,064% | $149-99.9% | $190.54K+37,981% | ||
| -$5.86K— | —— | -$17.51K-486% | $4.53K+119% | -$23.27K-202% | ||
| —— | -$682.750.0% | -$682.750.0% | -$682.750.0% | -$682.75— | ||
| $90.95K— | $0-100% | $63.07K-45.6% | $115.91K+102% | -$6.3M-3,285% | ||
| —— | —— | —— | —— | -$1.26M-878% | ||
| -$5.08M-33.4% | -$3.81M+75.9% | -$15.81M-303% | -$3.92M+11.4% | -$4.43M+41.3% | ||
| —— | —— | —— | -$3.91M+11.5% | -$4.41M+41.5% | ||
| -$5.08M-33.4% | -$3.81M+75.9% | -$15.81M-303% | -$3.92M+11.4% | -$4.43M+41.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Dogwood Therapeutics profitable?
- Dogwood Therapeutics is not currently profitable: it reported a net loss of $28.3M over the trailing twelve months.
- What is Dogwood Therapeutics's earnings per share?
- Dogwood Therapeutics's diluted EPS over the trailing twelve months is $-18.79.
- Where does Dogwood Therapeutics's income statement data come from?
- Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.